Related Experiment Video

Updated: Aug 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Immunoadsorption therapy and complement activation

J Pták1, J Lochman

  • 1Blood Center of University Hospital, 17 listopadu 833, 708 52 Ostrava-Poruba, Czech Republic. jan.ptak@fnspo.cz

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|June 10, 2005
PubMed

Insights

Immunoadsorption therapy for myasthenia gravis activates the complement system, indicated by C3, C4, CH50, and TCC changes. Long-term treatment may lead to reduced complement activation, suggesting an immunomodulatory effect.

Area of Science:

  • Immunology
  • Neurology

Background:

  • Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions.
  • Immunoadsorption therapy is used to treat myasthenia gravis by removing pathogenic antibodies.

Purpose of the Study:

  • To investigate complement activation during immunoadsorption therapy for myasthenia gravis.
  • To assess the impact of long-term immunoadsorption on complement system reactivity.

Main Methods:

  • Studied complement activation markers (C3, C4, CH50, TCC) in six myasthenia gravis patients undergoing immunoadsorption therapy (Ig-ADSOPAK).
  • Analyzed complement levels before and after each procedure over a mean therapy duration of 18.6 months.

Main Results:

  • Immunoadsorption caused a decrease in C3 and C4 levels (median 21.19% and 19.68%).
  • Statistically significant complement activation was observed, with median TCC accrual of 60.21% and CH50 decrease of 23.24%.
  • No clinical signs of complement activation were noted. A decrease in TCC activation was observed with increasing procedures, significant in 3/5 patients.

Conclusions:

  • Immunoadsorption therapy for myasthenia gravis transiently activates the complement system.
  • Long-term therapy may induce an immunomodulatory effect, leading to reduced complement system reactivity.
  • Further studies with larger patient cohorts are needed to confirm these findings.

More Related Videos

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview